Medistim ASA (0OCD) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Very good morning, everyone, and welcome to Medistim's Second Quarter and First Half twenty twenty six Financial Results Presentation. My name is Karl Krugsta, and together with CFO, Thomas Jakobsen, we are here to go through the results. As always, we like to just remind ourselves about Medistim's track record and we are looking back on decades of growth both in sales and in operating profit. And that has been our promise to our shareholders to deliver constant profitable growth also going forward. If you look at just the recent period from 2021 to 2025, we are looking to 13% annualized growth in sales. So definitely a strong track record to look back on. So with that, we are entering into the second quarter. The second quarter last year was a strong comparable and we're seeing that we are beating it with high margin and also setting new records for both sales and EBIT. So this is definitely strong performance. As we can see, we are delivering another record quarter with sales reaching million. We can see here also that due to the strong Norwegian currency versus euros and dollars, we have a negative currency effect here. And adjusting for this, we are actually looking at currency neutral sales development for total sales, up 27.5%, so a very good development. Our own products are growing by 33.6% currency neutral and we can see that all the sales regions are really contributing nicely to this result. Americas is up 46.3%, EMEA is up 19.4% and Asia Pacific up 22.4%. The third party products is down 7%. We are also setting then a new record for quarterly operating profit, delivering SEK65.3 million in EBIT this quarter. This gives an EBIT margin on the high side at 32.3%, very much driven by the strong sales development of our own products. We will see also that this...